ArticleClinical immunology (Orlando, Fla.)2016
Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction.
Article in Clinical immunology (Orlando, Fla.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Spatiotemporal orchestration of the salivary gland immune microenvironment in Sjögren's disease: a multidimensional framework of epithelial licensing, lymphoid neogenesis, and stromal remodeling.Frontiers in immunology · 2026Review
- The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances.Frontiers in immunology · 2025Review
- Chemokines and lymphocyte homing in Sjögren's syndrome.Frontiers in immunology · 2024Review
- Marginal Zone B (MZB) Cells: Comparison of the Initial Identification of Immune Activity Leading to Dacryoadenitis and Sialadenitis in Experimental Sjögren's Syndrome.International journal of molecular sciences · 2023Article
- A MZB Cell Activation Profile Present in the Lacrimal Glands of Sjögren's Syndrome-Susceptible C57BL/6.NOD-International journal of molecular sciences · 2022Article
- Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.Frontiers in immunology · 2022Review
- Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis.Brain communications · 2022Review
- Role of the Innate Immunity Signaling Pathway in the Pathogenesis of Sjögren's Syndrome.International journal of molecular sciences · 2021Review
- Early Covert Appearance of Marginal Zone B Cells in Salivary Glands of Sjögren's Syndrome-Susceptible Mice: Initiators of Subsequent Overt Clinical Disease.International journal of molecular sciences · 2021Article
- CXCL13 Neutralization Attenuates Neuropsychiatric Manifestations in Lupus-Prone Mice.Frontiers in immunology · 2021Article
- Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures.Clinical and experimental medicine · 2020Article
- Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis.ImmunoTargets and therapy · 2020Review
- B-cell activating factor receptor expression is associated with germinal center B-cell maintenance.Experimental and therapeutic medicine · 2019Article
- Current and Emerging Evidence for Toll-Like Receptor Activation in Sjögren's Syndrome.Journal of immunology research · 2018Review
- T Cells That Help B Cells in Chronically Inflamed Tissues.Frontiers in immunology · 2018Review
- Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Frontiers in immunology · 2018Review
- Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome.Annals of the rheumatic diseases · 2018Article
- Myd88 is required for disease development in a primary Sjögren's syndrome mouse model.Journal of leukocyte biology · 2017Article
- Systemic manifestations of primary Sjögren's syndrome in the NOD.B10Sn-H2Clinical immunology (Orlando, Fla.) · 2017Article
- Sex differential association of dermatomyositis with Sjögren syndrome.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Sjögren's syndrome (SS) is a debilitating autoimmune disease. Patients with SS may develop xerostomia. This process is progressive, and there are no therapeutics that target disease etiology. We hypothesized BAFF receptor (BAFFR) blockade would mitigate SS disease development, and neutralization of CXCL13 and BAFF signaling would be more efficacious than BAFFR blockade alone. We treated NOD/ShiLtJ SS mice with soluble BAFF receptor (BAFFR-Fc) or anti-CXCL13/BAFFR-Fc in combination, prior to the development of clinical disease. Our results show treatment with BAFFR-Fc reduced peripheral B cell numbers and decreased sialadenitis. In addition, this treatment reduced total serum immunoglobulin as well as IgG and IgM specific anti-nuclear autoantibodies. NOD/ShiLtJ mice treated with BAFFR-Fc and anti-CXCL13 antibody were protected from salivary deficits. Results from this study suggest blockade of CXCL13 and BAFFR together may be an effective therapeutic strategy in preventing salivary hypofunction and reducing autoantibody titers and sialadenitis in patients with SS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.